Author

Jake P. Taylor-King

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1

Frequent Co-Authors

Artem Kaznatcheev· 2 shared David Robert Grimes· 2 shared Andrew DhawaniD· 1 shared Andriy MarusykiD· 1 shared Arturo Araujo· 1 shared Benedikt Bauer· 1 shared Daria Myroshnychenko· 1 shared David BasantaiD· 1 shared

Activity by Year

2016-2017 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Artem Kaznatcheev

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia

Artem Kaznatcheev, David Robert Grimes, Robert Vander Velde, Vincent Cannataro, Etienne Baratchart, Andrew Dhawan, Lin Liu, Daria Myroshnychenko, Jake P. Taylor-King, Nara Yoon, Eric Padron, Andriy Marusyk, David Basanta

The paper challenges the classic U-shape model of resistance by proposing alternative population-level models for ruxolitinib resistance in CMML and explores the role of oxygen and cytokine signaling in resistance dynamics.

bioRxiv · Oct 30, 2017 · PreprintCancer Biology

Toxicity Management in CAR T cell therapy for B-ALL: Mathematical modelling as a new avenue for improvement.

Shalla Hanson, David Robert Grimes, Jake P. Taylor-King, Benedikt Bauer, Pravnam I. Warman, Ziv Frankenstein, Artem Kaznatcheev, Michael J. Bonassar, Vincent L. Cannataro, Zeinab Y. Motawe, Ernesto A. B. F. Lima, Sungjune Kim, Marco L. Davila, Arturo Araujo

This paper develops a mathematical model to explore toxicity in CAR T cell therapy for B-ALL, finding that initial tumour burden is a stronger predictor of toxicity than CAR T cell dose.

bioRxiv · Apr 22, 2016 · PreprintCancer Biology